In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.

• New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.
• Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance.
• Diagnostics’ role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes.

Note: Information in this post was accurate at the time of its posting.

Resources

• Therapeutics testing: A clear path to accurate answers
• Therapeutics testing at Mayo Clinic Laboratories
• WHO warns of widespread resistance to common antibiotics worldwide
• Tests for infectious disease detection and identification

Connect with Us

• Is there a question or topic you’d like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu.
• Learn more about our hosts and guests and connect with them on social media.
  • Bobbi Pritt, M.D. Bio | LinkedIn
  • Bill Morice, M.D., Ph.D. Bio | LinkedIn
  • Paul Jannetto, Ph.D. Bio | LinkedIn

Published October 16, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:

• FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.
• PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.
• Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.

Resources

• Find past “Answers From the Lab” podcasts on LDTs and PAMA

Published October 2, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, discuss the latest developments in self-collection testing for women’s health and beyond. Together, they explore:

• New podcast format launching (00:01): Dr. Pritt previews exciting changes coming to “Answers From the Lab.”
• Emerging self-collection tests (01:21): Explore the growing range of self-collection tests now available for use in both clinical settings and at home.
• Validation of self-collection tests (03:19): Learn how laboratorians validated recent self- and home-collection tests to ensure quality and accuracy.
• Benefits for patients and public health (06:56): Understand the benefits self-collection tests offer to patients and how the tests impact public health.
• Limitations and implementation considerations (08:23): Review key factors to consider when incorporating self-collection testing into clinical care.
• Future innovation (11:34): Insights into where self-collection testing may evolve in the years ahead.